<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02888652</url>
  </required_header>
  <id_info>
    <org_study_id>XY3-CLOP1507A01</org_study_id>
    <secondary_id>ChiCTR-OOC-16009006</secondary_id>
    <nct_id>NCT02888652</nct_id>
  </id_info>
  <brief_title>Study on the Registration of Coronary Heart Disease Patients Undergoing PCI</brief_title>
  <official_title>Multivariate Analysis of Platelet Reactivity Variety in Patients With Coronary Heart Disease After PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Third Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study on the registration of coronary heart disease patients undergoing PCI in Chinese's&#xD;
      population. Get the incidence of adverse events in these patients after PCI, a clear type of&#xD;
      adverse reaction, forms, influencing factors, to establish risk management processes,&#xD;
      clinical safety and reasonable treatment, and provide the basis for further research and&#xD;
      reference.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dual antiplatelet therapy, comprising a low-dose aspirin and a kind of P2Y12 Receptor&#xD;
      Inhibitors, has been the mainstay of the management in patients with acute coronary syndromes&#xD;
      and/or undergoing Percutaneous Coronary Intervention (PCI). While variability to P2Y12&#xD;
      receptor inhibitors is common in patients and is a major cause of adverse cardiovascular&#xD;
      events. Low response to P2Y12 receptor inhibitors will result high platelet reactivity (HPR)&#xD;
      and patients who exhibit HPR are at increased risk of atherothrombotic occlusion events. Vice&#xD;
      versa, high response to P2Y12 receptor inhibitors will lead to low platelet reactivity (LPR)&#xD;
      and increase the risk of hemorrhage.Now, the absence of a universal definition of therapeutic&#xD;
      window for different racial and actual clinical situations and lacking the gold standard test&#xD;
      to quantify it limit the use in clinic practice.So this clinical trial try to use patient's&#xD;
      platelet reactivity combine with type of adverse reaction, forms, influencing factors to find&#xD;
      a proper therapeutic windows for P2Y12 receptor inhibitors in Chinese people.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>within 1 year after PCI</time_frame>
    <description>ischemic and bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood drug concentration</measure>
    <time_frame>at 5-7 days, 1month, 3 months, 6 months and 12 months after taking anti-platelet agents</time_frame>
    <description>Clopidogrel and Ticagrelor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mild to moderate adverse events</measure>
    <time_frame>within 1 year after PCI</time_frame>
    <description>renal function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet activity</measure>
    <time_frame>at 12- 24 hours, 1 month, 3 months, 6 months and 12 months after PCI</time_frame>
    <description>Platelet activity</description>
  </secondary_outcome>
  <enrollment type="Actual">1500</enrollment>
  <condition>Coronary Heart Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antiplatelet agents(Clopidogrel or Ticagrelor)</intervention_name>
    <description>Clinical physicians according to patients condition to give different antiplatelet agents(Clopidogrel or Ticagrelor).We only observe clinical curative effect.</description>
    <other_name>Clopidogrel or Ticagrelor</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      gene test&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with coronary artery disease treated with aspirin and clopidogrel after successful&#xD;
        stent implantation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chinese's patients diagnosed with coronary heart disease and accept stent&#xD;
             implantation.&#xD;
&#xD;
          -  Accept aspirin and P2Y12 receptor inhibitors (clopidogrel or ticagrelorwere）after&#xD;
             stent implantation.&#xD;
&#xD;
          -  Willingness and ability to sign informed consent.&#xD;
&#xD;
          -  Can communicate effectively and complete the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Occurrence of a major complication during the procedure of percutaneous coronary&#xD;
             intervention or before platelet function testing.&#xD;
&#xD;
          -  Allergy or intolerance to aspirin or P2Y12 receptor inhibitors (Clopidogrel or&#xD;
             Ticagrelor）&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GuoPing Yang, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yu Cao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jingle Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2016</study_first_posted>
  <last_update_submitted>October 9, 2019</last_update_submitted>
  <last_update_submitted_qc>October 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>PCI</keyword>
  <keyword>Anti-Platelet Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

